| CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response S Chatterjee, A Daenthanasanmak, P Chakraborty, MW Wyatt, P Dhar, ... Cell metabolism 27 (1), 85-100. e8, 2018 | 229 | 2018 |
| NKG2D and its ligands in cancer P Dhar, JD Wu Current opinion in immunology 51, 55-61, 2018 | 182 | 2018 |
| Anticancer activity of Ophiobolin A, isolated from the endophytic fungus Bipolaris setariae DR Bhatia, P Dhar, V Mutalik, SK Deshmukh, SA Verekar, DC Desai, ... Natural Product Research 30 (12), 1455-1458, 2016 | 40 | 2016 |
| Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 … J Zhang, PS Larrocha, B Zhang, D Wainwright, P Dhar, JD Wu Journal for immunotherapy of cancer 7, 1-15, 2019 | 27 | 2019 |
| NK cell plasticity in cancer S Liu, P Dhar, JD Wu Journal of Clinical Medicine 8 (9), 1492, 2019 | 26 | 2019 |
| Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy F Basher, P Dhar, X Wang, DA Wainwright, B Zhang, J Sosman, Z Ji, ... Journal of hematology & oncology 13, 1-16, 2020 | 24 | 2020 |
| Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation P Dhar, F Basher, Z Ji, L Huang, S Qin, DA Wainwright, J Robinson, ... Communications Biology 4 (1), 905, 2021 | 10 | 2021 |
| P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) shows anti-tumor activity in triple … VR Agarwal, D Bhatia, A Joshi, P Mishra, KG Bharadwaj, P Menon, ... Cancer Research 74 (19 Supplement), 4521-4521, 2014 | 3 | 2014 |
| The clinical impact of soluble natural killer cell group 2-member D (NKG2D) receptor ligands on tumor tumorigenicity and anti-tumor immunity. AV Serritella, P Saenz-Lopez, P Dhar, S Liu, J Wu Journal of Clinical Oncology 41 (16_suppl), e14557-e14557, 2023 | 1 | 2023 |
| The Human Soluble NKG2D Ligand Differentially Impacts Tumorigenicity and Progression in Temporal and Model-Dependent Modes AV Serritella, P Saenz-Lopez Larrocha, P Dhar, S Liu, MM Medd, S Jia, ... Biomedicines 12 (1), 196, 2024 | | 2024 |
| 1011 Antibody targeting NKG2D ligands MICA/B to unleash anti-tumor immunity of NK and ILC1 cells S Liu, T Smith, L Zhu, P Dhar, J Wu Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Human NKG2D Ligand Regulation of NK Cell Functions and Metabolism: From Molecular Mechanisms to Therapeutics P Dhar Northwestern University, 2021 | | 2021 |
| Targeting metabolism to potentiate NK cell-based therapies P Dhar, JD Wu Successes and Challenges of NK Immunotherapy, 369-386, 2021 | | 2021 |
| Abstract A77: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual costimulation of CD8 T cells and enables sMIC+ tumors to respond to PD1/PD-L1 blockade … J Zhang, P Larrocha, P Dhar, J Wu Cancer Immunology Research 8 (3_Supplement), A77-A77, 2020 | | 2020 |
| Antibody targeting soluble NKG2D ligand sMIC sensitizes metastatic prostate tumor and other MIC+ tumors to PD1/PD-L1 blockade therapy in pre-clinical models JD Wu, J Zhang, P Larrocha, P Dhar CANCER RESEARCH 79 (13), 2019 | | 2019 |
| Human NKG2D ligand regulation of Natural Killer cell function and its implications in cancer and inflammation P Dhar, J Wu Cancer Research 78 (13 Supplement), 3802-3802, 2018 | | 2018 |
| Modulation of signaling preference of NK cells by different forms of NKG2D ligands and its implications P Dhar, F Basher, J Zhang, J Wu The Journal of Immunology 198 (1 Supplement), 130.27-130.27, 2017 | | 2017 |
